Modulation of c-Met signaling and cellular sensitivity to radiation: Potential implications for therapy

Cancer

Volumn 119, Issue 10, 2013, Pages 1768-1775

  Bhardwaj, Vikas ^a   Cascone, Tina ^a   Cortez, Maria Angelica ^a   Amini, Arya ^a,b   Evans, Jaden ^a,c   Komaki, Ritsuko U ^a   Heymach, John V ^a   Welsh, James W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

c Met; clinical targeting; DNA damage; epithelial mesenchymal transition; radiotherapy

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMUVATINIB; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DN 30; ERLOTINIB; FIBRONECTIN; FICLATUZUMAB; FOCAL ADHESION KINASE; FORETINIB; HEPATOCYTE NUCLEAR FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; OA 5D5; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAD51 PROTEIN; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; TAK 701; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIMENTIN;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; COLON CARCINOMA; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; FAILURE FREE SURVIVAL; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; IRRADIATION; LOCAL FAILURE FREE SURVIVAL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANILIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; DNA DAMAGE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; PYRROLIDINONES; QUINAZOLINES; QUINOLINES; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84877578990     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27965     Document Type: Review

References (86)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-925.
2. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994; 77: 261-271.
3. Sipeki S, Bander E, Buday L, et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal. 1999; 11: 885-890.
4. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M,. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000; 20: 8513-8525.
5. Trusolino L, Bertotti A, Comoglio PM,. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell. 2001; 107: 643-654.
6. Bertotti A, Comoglio PM, Trusolino L,. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol. 2006; 175: 993-1003.
7. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer. 1996; 74: 1862-1868.
8. Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol. 2001; 158: 1451-1463.
9. Zarnegar R,. Regulation of HGF and HGFR gene expression. EXS. 1995; 74: 33-49.
10. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G,. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood. 2003; 101: 4816-4822.
11. Okano J, Shiota G, Kawasaki H,. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver. 1999; 19: 151-159.
12. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF,. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood. 1992; 80: 2454-2457.
13. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF,. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A. 1994; 91: 4731-4735.
14. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002; 16: 108-110.
15. Rahimi N, Tremblay E, McAdam L, Park M, Schwall R, Elliott B,. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 1996; 7: 263-270.
16. Yi S, Tsao MS,. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia. 2000; 2: 226-234.
17. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008; 47: 1025-1037.
18. Puri N, Ahmed S, Janamanchi V, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007; 13: 2246-2253.
19. Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res. 2002; 8: 2273-2285.
20. Abounader R, Laterra J,. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005; 7: 436-451.
21. Liu Y, Li Q, Zhu L,. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 2012; 98: 105-112.
22. Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012; 18: 2269-2277.
23. Moriyama T, Kataoka H, Koono M, Wakisaka S,. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors. (Review). Int J Mol Med. 1999; 3: 531-536.
24. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997; 57: 5391-5398.
25. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002; 94: 3210-3218.
26. Inno A, Di Salvatore M, Cenci T, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 2011; 10: 325-332.
27. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR,. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 2011; 17: 472-482.
28. Cheng TL, Chang MY, Huang SY, et al. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest. 2005; 128: 1453-1460.
29. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002; 8: 620-627.
30. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007; 98: 1006-1013.
31. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer. 2004; 90: 1555-1562.
32. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27: 1667-1674.
33. Stoker M, Gherardi E, Perryman M, Gray J,. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987; 327: 239-242.
34. Rosen EM, Knesel J, Goldberg ID, et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer. 1994; 57: 706-714.
35. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C,. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 1993; 123: 223-235.
36. Santos OF, Barros EJ, Yang XM, et al. Involvement of hepatocyte growth factor in kidney development. Dev Biol. 1994; 163: 525-529.
37. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 1997; 94: 701-706.
38. Otsuka T, Takayama H, Sharp R, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998; 58: 5157-5167.
39. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST,. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 2002; 62: 5126-5128.
40. Pear WS, Simon MC,. Lasting longer without oxygen: the influence of hypoxia on Notch signaling. Cancer Cell. 2005; 8: 435-437.
41. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM,. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3: 347-361.
42. Jahn SC, Law ME, Corsino PE, et al. An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett. 2012; 326: 183-190.
43. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO,. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer. 2007; 43: 1214-1224.
44. Andarawewa KL, Erickson AC, Chou WS, et al. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res. 2007; 67: 8662-8670.
45. Zhou YC, Liu JY, Li J, et al. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys. 2011; 81: 1530-1537.
46. Zhang X, Li X, Zhang N, Yang Q, Moran MS,. Low doses ionizing radiation enhances the invasiveness of breast cancer cells by inducing epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2011; 412: 188-192.
47. Kawamoto A, Yokoe T, Tanaka K, et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep. 2012; 27: 51-57.
48. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30: 1926-1933.
49. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359: 2235-2241.
50. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A. 1993; 90: 1937-1941.
51. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001; 158: 1111-1120.
52. Atabey N, Gao Y, Yao ZJ, et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem. 2001; 276: 14308-14314.
53. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 2000; 60: 342-349.
54. Fan S, Wang JA, Yuan RQ, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene. 1998; 17: 131-141.
55. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene. 2000; 19: 2212-2223.
56. Yuan R, Fan S, Achary M, Stewart DM, Goldberg ID, Rosen EM,. Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor//scatter factor in the setting of DNA damage. Cancer Res. 2001; 61: 8022-8031.
57. Medova M, Aebersold DM, Zimmer Y,. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer. 2012; 130: 728-734.
58. Hu SY, Duan HF, Li QF, et al. Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage. Acta Pharmacol Sin. 2009; 30: 1415-1420.
59. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V,. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer. 2001; 96: 41-54.
60. Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH,. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011; 33: 1458-1466.
61. Bhardwaj V, Zhan Y, Cortez MA, et al. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012; 7: 1211-1217.
62. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011; 103: 645-661.
63. Qian LW, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 2003; 104: 542-549.
64. Chu SH, Ma YB, Zhu ZA, et al. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg Neurol. 2007; 68: 610-613; discussion 613-614.
65. Schweigerer L, Rave-Frank M, Schmidberger H, Hecht M,. Sublethal irradiation promotes invasiveness of neuroblastoma cells. Biochem Biophys Res Commun. 2005; 330: 982-988.
66. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007; 104: 19936-19941.
67. Chu SH, Zhu ZA, Yuan XH, Li ZQ, Jiang PC,. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol. 2006; 80: 143-149.
68. Michaud NR, Jani JP, Hillerman S, et al. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs. 2012; 4 (6).
69. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B,. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009; 4: 69.
70. Medova M, Aebersold DM, Blank-Liss W, et al. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. Genes Cancer. 2010; 1: 1053-1062.
71. Yu H, Li X, Sun S, Gao X, Zhou D,. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem Biophys Res Commun. 2012; 427: 659-665.
72. Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B,. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012; 84: e525-e531.
73. Lin CI, Whang EE, Donner DB, et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010; 8: 1217-1226.
74. Buchanan IM, Scott T, Tandle AT, et al. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med. 2011; 15: 1999-2006.
75. Lal B, Xia S, Abounader R, Laterra J,. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005; 11: 4479-4486.
76. Peters S, Adjei AA,. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012; 9: 314-326.
77. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011; 29: 3307-3315.
78. Goldberg J, Demetri GD, Choy E, et al. Preliminary results from phase II study of ARQ 197 in patients with microphthalmia transcription factor family-associated tumors [abstract]. J Clin Oncol. 2009; 27 (suppl 15):Abstract 10502.
79. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10: 2298-2308.
80. Aftab DT, McDonald DM,. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 2011; 13: 703-709.
81. Fizazi K, Albiges L, Massard C, Escudier B, Loriot Y,. Novel and bone-targeted agents for CRPC. Ann Oncol. 2012; 23 (suppl 10): x264-x267.
82. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006; 66: 1721-1729.
83. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011; 13: 437-446.
84. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM,. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998; 111 (pt 2): 237-247.
85. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A. 2006; 103: 5090-5095.
86. Spigel DR, Ervin T, Ramlau R, et al. Randomized multicenter double-blind placebo-controlled phase ii study evaluating metmab, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer [abstract]. Ann Oncol. 2010; 21 (Suppl 8):Abstract LBA15.